Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Lenalidomide is a thalidomide analog. Immune modulatory drug and cereblon binding compound. Induces ubiquitination and degradation of casein kinase (CK) 1α by the E3 ubiquitin ligase CRL4CRBN. Also TNF-α inhibitor and angiogenesis inhibitor. Promotes degradation of transcription factor SALL4.
Lenalidomide is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Antiviral Library and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 259.26. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.86 mL||19.29 mL||38.57 mL|
|5 mM||0.77 mL||3.86 mL||7.71 mL|
|10 mM||0.39 mL||1.93 mL||3.86 mL|
|50 mM||0.08 mL||0.39 mL||0.77 mL|
References are publications that support the biological activity of the product.
Petzold et al (2016) Structural basis of lenalidomide-induced CK1a degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532 127 PMID: 26909574
Krönke et al (2015) Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523 183 PMID: 26131937
Donovan et al (2018) Thal. promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray Syndrome. Elife 7 e38430 PMID: 30067223
Chamberlain et al (2019) Evolution of cereblon-mediated protein degradation as a therapeutic modality. ACS Med.Chem.Lett. 10 1592 PMID: 31857833
If you know of a relevant reference for Lenalidomide, please let us know.
Keywords: Lenalidomide, Lenalidomide supplier, tumor, necrosis, factor, 1α, alpha, alfa, TNF, angiogenesis, inhibitor, cereblon, binder, ubiquitin, CELMoD, E3, ligase, modulators, SALL4, casein, kinase, CK1, degrades, immunomodulators, immunomodulatory, imide, IMiDs, molecular, glue, modulating, CELMoDs, Ubiquitin, Ligases, Cytokines, Antiangiogenics, Other, Transcription, Factors, Molecular, Glues, 6305, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Lenalidomide. Do you know of a great paper that uses Lenalidomide from Tocris? Please let us know.
Average Rating: 4 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia